July 2020 Investor Update
July 2020 Investor Update
Race Oncology is please update our shareholders on the clinical progress of bisantrene. This talk was presented by Race Oncology’s CSO Dr Daniel Tillett at the IRD Invest virtual conference on the 29th July...
Race Oncology 2019 Annual General Meeting Presentation
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene. • Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00) • Race’s 5 Path Strategy | Dr Daniel Tillett...
The devastating impact of AML and why we need hope
The devastating impact of AML and why we need hope
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers....
Race Oncology produces first batch of Bisantrene for sale
Race Oncology produces first batch of Bisantrene for sale
Race Oncology Limited (RAC) is pleased to announce it has produced its first good manufacturing practice (GMP) batch of cancer drug Bisantrene. The first batch will be enough to treat up to sixty patients, with...
